Novo’s oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Study reveals sex-specific differences in microglial response to CSF1R inhibition

Researchers investigate the sex-dependent microglial response to a colony-stimulating factor 1 receptor (CSF1R) inhibitor.

January 24, 2025

Are ‘Ketamine Bros’ Ruining It for Everyone Else? | Psychedelic Invest

The psychedelics industry stands at a crossroads, marked by groundbreaking therapeutic achievements and concerning trends of misuse. Ketamine, once a revered medical solution, is increasingly

May 1, 2024

Alarming Rise of AI Voice Deepfakes: Waging War on Healthcare

Aaron Painter, CEO of Nametag Imagine you’re an IT professional for a large health system. A resident physician calls and says he must urgently send

August 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.